Improving medication adherence in chronic pediatric health conditions: A focus on ADHD in youth

Current Pharmaceutical Design

Volumn 16, Issue 22, 2010, Pages 2416-2423

  Chacko, Anil ^a,b,c   Newcorn, Jeffrey H ^c   Feirsen, Nicole ^b   Uderman, Jodi Z ^b  

^a CITY UNIVERSITY OF NEW YORK   (United States)

^b CITY UNIVERSITY OF NEW YORK   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

ADHD; Adherence; Compliance; Medication; Pediatric; Review; Stimulant medication

Indexed keywords

ADOLESCENT; ATTENTION DEFICIT DISORDER; BEHAVIOR THERAPY; HEALTH CARE SYSTEM; HUMAN; PATIENT COMPLIANCE; PATIENT EDUCATION; PEER GROUP; PRIORITY JOURNAL; REVIEW; SOCIOECONOMICS;

ADOLESCENT; ADOLESCENT BEHAVIOR; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; CHILD BEHAVIOR; CHRONIC DISEASE; HUMANS; MODELS, THEORETICAL; PATIENT COMPLIANCE; PATIENT EDUCATION AS TOPIC; SOCIAL SUPPORT; SOCIOECONOMIC FACTORS;

EID: 77955605939     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210791959908     Document Type: Review

References (75)

1. Newacheck PW, McManus M, Fox HB. Access to health care for children with special health care needs. Pediatrics 2000; 105: 760-6.
2. World health organization. Adherence to long term therapies: A call to action. World health organization: Switzerland 2003.
3. Milgrom H, Bender B, Ackerson L. Noncompliance and treatment failure in children with asthma. J Allergy Clin Immunol 1996; 98: 1051-7.
4. Kennard BD, Stewart SM, Olvera R. Nonadherence in adolescent oncology patients: Preliminary data on psychological risk factors and relationships to outcome. J Clin Psychol Med Settings 2004; 11: 31-9.
5. nd ed. New York: Springer 2009.
6. Drotar D, Greenley RN, Demeter CA. Adherence to pharmacological treatment for juvenile bipolar disorder. J Am Acad Child Adol Psychiatry 2007; 46: 831-9.
7. Ekberg H, Kyllonen L, Madsen S. Clinicians underestimate gastrointestinal symptoms and overestimate quality of life in renal transplant recipients: A multinational survey of nephrologists. Transplantation 2007; 84: 1052-954.
8. Fredericks EM, Magee JC, Opipari-Arrigan L. Adherence and health-related quality of life in adolescent liver transplant recipients. Pediatr Transplant 2008; 12: 289-99.
9. Hommel KA, Davis CM, Baldassano RN. Medication adherence and quality of life in pediatric inflammatory bowel disease. J Pediatr Psychol 2008; 33: 867-74.
10. Kessler R, Berglan P, Demler O. Lifetime prevalence and age-ofonset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62: 593-603.
11. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Health Disorders, IV-TR. Washington: APA 2000.
12. Kessler R, Adler L, Barkley R. The Prevalence and Correlates of Adult ADHD in the United States: Results from the National Comorbidity Survey Replication. Am J Psychiatry 2006; 163: 716-23.
13. Molina B, Flory K, Hinshaw S. Delinquent behavior and emerging substance use in the MTA at 36 months: prevalence, course, and treatment effects. J Am Acad Child Adol Psychiatry 2007; 46: 1028-40.
14. Molina B, Hinshaw S, Swanson J. The MTA at 8 years: prospective follow-up of children treated for combined-type ADHD in a multisite study. J Am Acad Child Adolesc Psychiatry 2009; 48: 484-500.
15. Owens JS, Hoza B. The role of inattention and hyperactivity/impulsivity in the positive illusory bias. J Consult Clin Psychol 2003; 71: 680-91.
16. Shemesh E, Drotar D. Treatment Adherence. In: Textbook of Pediatric Psychosomatic Medicine. In press.
17. Stuber ML, Shemesh E, Seacord D. Evaluating nonadherence to immunosuppressant medications in pediatric liver transplant recipients. Pediatr Transplant 2008; 12: 284-8.
18. Charach A, Ickowicz, Schachar R. Stimulant treatment over five years" adherence, effectiveness, and adverse effects. J Am Acad Child Adolesc Psychiatry 2004; 43: 559-67.
19. Charach A, Volpe T, Boydell KM. A theoretical approach to medication adherence for children and youth with psychiatric disorders. Harv Rev Psychiatry 2008; 16: 126-35.
20. Barbaresi W, Katusic S, Colligan R. Long-term stimulant medication treatment of attention-deficit/hyperactivity disorder: results from a population study. J Dev Behav Pediatr 2006; 27: 1-10.
21. Winterstein AG, Gerhard T, Shuster J, et al. Utilization of pharmacologic treatment in youth with attention deficit/hyperactivity disorder in Medicaid database. Ann Pharmacother 2008; 42(1): 24-31.
22. Marcus SC, Wan GJ, Kemner JE, et al. Continuity of methylphenidate treatment for attention-deficit/ hyperactivity disorder. Arch Pediatr Adolesc Med 2005; 159(6): 572-8.
23. Perwien AR, Hall J, Swensen A, et al. Stimulant treatment patterns and compliance in children and adults with newly treated attentiondeficit/ hyperactivity disorder. J Manag Care Pharm 2004; 10(2): 122-9.
24. Miller AR, lalonde CE, McGrail KM. Children's persistence with methylphenidate therapy: a population based study. Can J Psychiatry 2004; 49: 761-8.
25. Firestone P. Factors associated with children's adherence to stimulant Medication. Am J Orthopsychiatry 1982; 52: 447-57.
26. Atzori P, Usala T, Carucci S. Predictive Factors for Persistent Use and Compliance of Immediate-Release Methylphenidate: A 36- Month Naturalistic Study. J Child Adolesc Psychopharm 2009; 19: 673-81.
27. Faraone SV, Biederman J, Zimmerman B. An analysis of patient adherence to treatment during a 1-year, open-label study of OROS methylphenidate in children with ADHD. J Atten Disord 2007; 11: 157-66.
28. Jensen P. Arnold E, Swanson J. Three-year follow-up of the NIMH MTA study. J Am Acad Child Adol Psychiatry 2007; 46: 989-1002.
29. McBride MC. An individual double-blind crossover trial for assessing methylphenidate response in children with attention deficit disorder. J Pediatr 1988; 113: 137-45.
30. Barkley RA, McMurray MB, Edelbrock CS, et al. Side effects of methylphenidate in children with attention deficit hyperactivity disorder: A systemic, placebo-controlled evaluation. Pediatrics 1990; 86: 184-92.
31. Thiruchelvam D, Charach A, Schachar RJ. Moderators and mediators of long-term adherence to stimulant treatment in children with ADHD. J Am Acad Child Adolesc Psychiatry 2001; 40: 922-8.
32. Olfson M, Marcus SC, Zhang HF, et al. Continuity of methylphenidate treatment of adults with attention-deficit/hyperactivity disorder. J Manag Care Pharm 2007; 13(7): 570-7.
33. Chou WJ, Chou MC, Tzang RF, et al. Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes. Psychiatry Clin Neurosci 2009; 63(2): 167-75.
34. Bussing R, Gary FA. Practice guidelines and parental ADHD treatment evaluations: friends or foes? Harv Rev Psychiatry 2001; 9: 223-33.
35. Charach A, Skyba A, Cook L. using stimulant medication for children with ADHD: what do parents say? A brief report. J Can Acad Child Adolesc Psychiatry 2006; 15: 75-83.
36. Bodenheimer T, Wagner EH, Grumbach K. Improving primary care for patients with chronic illness. JAMA 2002; 288: 1775-9.
37. Epstein JN, Langberg JN, Lichtenstein PK. Community-wide intervention to improve the attention-deficit/hyperactivity assessment and treatment practices of community physicians. Pediatrics 2008; 122: 19-27.
38. Tsai AC, Morton SC, Mangione CM. A meta-analysis of intervention to improve chronic care for chronic illness. Am J Manag Care 2005; 11: 478-88.
39. Charach A, Gajaria A, Skyba A, et al. Documenting adherence to psychostimulants in children with ADHD. J Can Acad Child Adolesc Psychiatry 2008; 17: 131-6.
40. Wolraich ML. Attention-deficit hyperactivity disorder. Semin Pediatr Neurol 2006; 13: 279-85.
41. Wu EQ, Birnbaum HG, Zhang HF. Health care costs of adults treated for attention-deficit/hyperactivity disorder who received alternative drug therapies. J Manag Care Pharm 2007; 13: 561-9.
42. Denney, Colin B, Rapport, et al. Predicting methylphenidate response in children with ADHD: Theoretical, empirical, and conceptual models. J. Am Acad Child Adolesc Psychiatry 1999; 38: 393-401.
43. Swanson JM, HInshaw SP, Arnold LE. Secondary evaluations of the MTA 36-month outcomes: propensity score and growth mixture model analyses. J Am Acad Child Adolesc Psychiatry 2007; 46: 1003-14.
44. Meaux JB, Hester C, Smih B. Stimulant medications: a trade-off? The lived experience of adolescents with ADHD. J Spec Pediatr Nurs 2006; 11: 214-26.
45. Gau SF, Shen H, Chou M. Determinants of adherence to methylphenidate and the impact of poor adherence on maternal and family measures. J Child Adolesc Psychopharm 2006; 16: 286-97.
46. Bussing R, Koro-Ljungberg ME, Gary F. Exploring help-seeking for ADHD symptoms: a mixed methods approach. Har Rev Psychiatry 2005; 13: 85-101.
47. Johnston C, Seipp C, Hommersen P. Treatment choices and experiences in attention deficit hyperactivity disorder: relations to parents' beliefs and attributions. Child Care Health Dev 2005; 31: 669-77.
48. Corkum P, RImer P, Shachar R. Parental knowledge of attentiondeficit hyperactivity disorder and opinions of treatment options: impact on enrollment and adherence to 12-month treatment trial. Can J Psychiatry 1999; 44: 1043-8.
49. Hansen DL, Hansen EH. Caught in a balancing act: parents dilemmas regarding their ADHD child's treatment with stimulant medication. Qual Health Res 2006; 16: 1267-85.
50. Christensen L, Sasané R, Hodgkins P. Pharmacological treatment patterns among patients with attention-deficit/hyperactivity disorder: retrospective claims-based analysis of a managed care population. Curr Med Res Opin 2010; 26: 977-89.
51. Rieppi R, Greenhill L, Ford R. Socioeconomic status as a moderator of ADHD treatment outcomes. J Am Acad Child Adolesc Psychiatry 2002; 41; 269-77.
52. Leslie LK, Plemmons D, Monn AR. Investigating ADHD treatment trajectories: listening to familiies' stories about medication use. J Dev Behav Peditr 2007; 28: 179-88.
53. Dosreis S, Zito JM, Safer DJ. Parental perceptions and satisfaction with stimulant medication for attention-deficit hyperactivity disorder. J Dev Behav Pediatr 2003; 24: 155-62.
54. Charach A, Gajaria A. Improving psychostimulant adherence in children with ADHD. Expert Rev Neurother 2008; 8: 1563-71.
55. Fishbein M, Triandis H, Kanfer F, et al. Factors influencing behavior and behavior change. In: Baum A, Revenson T, Singer J, Eds. Handbook of health psychology. Mahwah, NJ: Erlbaum 2001.
56. Kahana S, Drotar D, Frazier T. Meta-analysis of psychological interventions to promote adherence to treatment in pediatric chronic conditions. J Pediatr Psychol 2009; 33: 590-611.
57. Lemanek KL, Kamps J, Chung NB. Empirically supported treatments in pediatric psychology: Regimen adherence. J Pediatr Psychol 2001; 26: 253-75.
58. Chacko A, Wakschlag L, Hill C. Viewing preschool disruptive behavior disorders and ADHD through a developmental lens: what we know & what we need to know. Child Adolesc Psychiatric Clin N Am 2009; 18(3): 627-43.
59. Swanson JM, Elliott GR, Greenhill LL. Effects of stimulant medication on growth rates across 3 years in the MTA follow-up. J Am Acad Child Adolesc Psychiatry 2007; 46: 1015-27.
60. American Academy of Pediatrics/American Heart Association. American Academy of Pediatrics/American Heart Association clarification of statement on cardiovascular evaluation and monitoring of children and adolescents with heart disease receiving medications for ADHD. J Dev Behav Pediatr 2008; 29: 335.
61. Lambert NM, Hartsough CS. Prospective study of tobacco smoking and substance dependencies among samples of ADHD and non- ADHD participants. J Learn Disabil 1998; 31: 533-44.
62. Berman SM, Kuczenski R, McCracken JT. Potential adverse effects of amphetamine treatment on brain and behavior: a review. Mol Psychiatry 2009; 14: 123-42.
63. National Council on Patient Information and Education. Enhancing prescription medication adherence: a national action plan. Bethesda: National Council on Patient Information and Education 2007.
64. Johnston C, Mash E. Families of children with attention-deficit/ hyperactivity disorder: review and recommendations for future research. Clin Child Fam Psychol Rev 2001; 4: 3, 183-207
65. Chronis AM, Lahey BB, Pelham WE. Psychopathology and substance abuse in parents of children with attention-deficit/ hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2003; 42: 1424-32.
66. Deering KN, Shannon K, Sinclair H. Piloting a peer-driven intervention model to increase access and adherence to antiretroviral therapy and HIV care among street-entrenched HIV-positive women in vancouver. AIDS Patient Care STDs 2009; 23: 603-9.
67. Heisler M, Halasyamani L, Resnicow K. "I am not alone": the feasibility and acceptability of interactive voice response-facilitated telephone peer support among older adults with heart failure. Congest Fail 2007; 13: 149-57.
68. Sells D, Davidson L, Jewell C. The treatment relationship in peerbased and regular case management for clients with severe mental illness. Psychiatr Serv 2006; 57: 1179-84.
69. Olin SS, Hoagwood KE, Rodriguez J. The application of behavior change theory to family-based services: Improving parent empowerment in children's mental health. J Child Fam Stud 2009; 45: 1062-24.
70. Hoagwood KE, Green E, Kelleher K. Family advocacy, support and education in children's mental health: Results of a national survey. Adm Policy Men Health 2008; 35: 73-83
71. van Dulmen S, Sluijs E, van Dijk L. Furthering patient adherence: A position paper of the international expert forum on patient adherence based on an internet forum discussion. BMC Health Serv Res 2008; 8: 47.
72. Haynes RB, Ackloo E, Sahota N. Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2008; Issue 2. Art. No.: CD000011.
73. Berenguer B, La CC, de la Matta MJ, Martin-Calero MJ. Pharmaceutical care: past, present and future. Curr Pharm Des 2004; 10(31): 3931-3946.
74. Guilloteau D, Chalon S. PET and SPECT exploration of central monoaminergic transporters for the development of new drugs and treatments in brain disorders. Curr Pharm Des 2005; 11(25): 3237-3245.
75. Kirchheiner J, Seeringer A, Viviani R. Pharmacogenetics in psychiatry-- a useful clinical tool or wishful thinking for the future? Curr Pharm Des 2010; 16(2): 136-144.